Phenotype heterogeneity in Glucokinase-Maturity-Onset Diabetes of the Young (GCK-MODY) patients by Wędrychowicz, Anna et al.
246
ORI GI NAL AR TIC LE
Abstract
What is already known on this topic?
What this study adds?
Objective: The aim of the study was to evaluate the clinical phenotypes of glucokinase-maturity-onset diabetes of the young (GCK-
MODY) pediatric patients from Southwest Poland and to search for phenotype-genotype correlations. 
Methods: We conducted a retrospective analysis of data on 37 CGK-MODY patients consisting of 21 girls and 16 boys of ages 1.9-20.1 
(mean 12.5±5.2) years, treated in our centre in the time period between 2002 and 2013.
Results: GCK-MODY carriers were found in a frequency of 3% among 1043 diabetes mellitus (DM) patients and constituted the second 
most numerous group of DM patients, following type 1 DM, in our centre. The mean age of GCK-MODY diagnosis was 10.4±4.5 years. 
The findings leading to the diagnosis were impaired fasting glucose (IFG) (15/37), symptoms of hyperglycemia (4/37), and a GCK-MODY 
family history (18/37). Mean fasting blood glucose level was 6.67±1.64 mmol/L. In the sample, there were patients with normal values 
(4/37), those with DM (10/37), and IFG (23/37). In OGTT, 120 min glucose level was normal in 8, diabetic in 2, and characteristic for 
glucose intolerance in 27 of the 37 cases. Twelve of the 37 cases (32%) were identified as GCK-MODY carriers. In the total group, mean 
C-peptide level was 2.13±0.65 ng/mL and HbA1c was 6.26±0.45% (44.9±-18 mmol/mol). Thirty-two patients had a family history of 
DM. DM autoantibodies were detected in two patients. The most common mutations were p.Gly318Arg (11/37) and p.Val302Leu (8/37). 
There was no correlation between type of mutations and plasma glucose levels. 
Conclusion: The phenotype of GCK-MODY patients may vary from those characteristic for other DM types to an asymptomatic state with 
normal FG with no correlation with genotype. 
Keywords: Glucokinase-Maturity-Onset Diabetes of the Young, GCK-MODY, children, adolescents, genotype, phenotype
This paper presents the detailed clinical presentation of GCK-MODY patients. Only 32% of all analyzed GCK-MODY carriers fulfilled DM 
diagnostic criteria, the rest presented with impaired fasting glucose or glucose intolerance. Our clinical data could help to identify GCK-
MODY patients among patients with DM. The proper diagnosis could avoid insulin therapy in young patients which had previously been 
misdiagnosed as type 1 DM.
Monogenic glucokinase-maturity-onset diabetes of the young (GCK-MODY) is the second most common type of diabetes mellitus (DM) 
after type 1 DM in a population of children and adolescents in Central Europe. Since it has been possible to genetically test patients with 
DM, the number of CGK-MODY patients in Poland has been increasing.
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Introduction 
Maturity-onset diabetes of the young (MODY) is a monogenic 
form of diabetes inherited in an autosomal dominant way 
(1,2). There are over 800 known mutations associated with 
MODY and new ones are being discovered all the time (3). 
Glucokinase-maturity-onset diabetes of the young (GCK-
MODY), also known as MODY type 2, is the most common 
type of the monogenic diabetes in Poland (4), and, along with 
a HNF1A- MODY, is one of the most common in the world. 
It is caused by a heterozygous mutation in the glucokinase 
gene on chromosome 7 (5). Glucokinase in the pancreatic 
beta cells senses increased blood glucose levels and 
controls the release of insulin. The heterozygous mutation 
in the glucokinase-coding gene results in a changed insulin 
threshold and therefore persistent hyperglycemia (6). As the 
hyperglycemia is mild and does not progress or cause any 
long-term complications, it may remain unnoticed (7). 
GCK-MODY patients are usually non-obese, do not require 
treatment, and do not have vascular complications. This is 
the reason why it is important to differentiate this type from 
diabetes mellitus type 1 and type 2 (DM1 and DM2) in order 
to avoid unnecessary treatment (3,8,9,10). It should also be 
kept in mind that at the beginning, MODY was considered as 
a rare form of diabetes, however, it is probably much more 
common than assumed but often remains undiagnosed. By 
spreading knowledge of the existence of groups of diabetes 
such as MODY, and through the possibility of molecular 
testing, we should be able to change this situation. 
The aim of this present study was to evaluate the clinical 
phenotype of GCK-MODY patients from Southwestern 
Poland treated in our department and also to search for 
phenotype-genotype correlations.
Methods
For this retrospective analysis, of all 1043 patients with 
DM treated in the Department of Pediatric and Adolescent 
Endocrinology in Cracow, we selected 37 (21 girls and 16 
boys) aged between 1.92 and 20.1 years, with a mean age 
of 12.5±5.2 years, and with genetically confirmed GCK-
MODY, which were included in the study. All participants 
and/or their parents gave their written informed consent to 
use their clinical data in scientific publications. All patients 
had been treated in our department in the years 2002-2013. 
The following data were analyzed in details: age at GCK-
MODY diagnosis, anthropometric data at diagnosis and during 
treatment, signs and symptoms at the time of diagnosis, medical 
history including course of pregnancy, birth parameters, and 
family history. Results of oral glucose tolerance test (OGTT), 
C-peptide, HbA1c, lipid profile, autoantibodies, and presence 
of other co-morbidities were also analyzed. 
The clinical molecular testing was performed in an approved 
laboratory, with results interpreted by a board-certified 
clinical molecular geneticist or molecular genetic pathologist 
or the equivalent, in accordance with the American College 
of Medical Genetics (ACMG) Standards and Guidelines 2015 
(11). The gene mutations were assessed in the Laboratory 
of Immunopathology and Genetics, Medical University of 
Lodz, Poland, which has achieved the International Quality 
Certificate ISO 9001:2008, a certificate of the Polish Society 
of Human Genetics. Molecular testing was performed by 
DNA sequencing performed using fluorescent-labeled 
terminating deoxynucleoside triphosphates with gene-
specific oligonucleotide primers and multiplex ligation-
dependent probe amplification to detect ezon deletions 
(MRC-Holland, Amsterdam, The Netherlands). Details of 
the molecular methods used in our patients were reported 
previously (4,12). The molecular testing was also performed 
in family members of patients including parents, siblings, 
and grandparents with impaired fasting glucose (IFG), 
glucose intolerance (GI), or DM.
Anthropometric measurements were taken in all patients. 
Height was measured to the nearest millimeter using a rigid 
stadiometer. Weight was measured to the nearest 0.1 kg 
using a calibrated balance scale. Reference data for Polish 
children were used for assessment (13). Body mass index 
(BMI) was calculated as weight in kilograms (kg) divided by 
the square of the height in meters (m2). 
The statistical analysis was performed using Statistica/
MS Exel programs. Student’s t-test was used to compare 
the analyzed groups. A p-value <0.05 was considered as 
statistically significant.
Results 
GCK-MODY carriers amounted for 3% of all DM patients 
in our center (37/1043). The mean age at diagnosis was 
10.4±4.5 years. The suspicion of GCK-MODY was based 
on different heterogeneous signs, symptoms, and results of 
laboratory tests. 14/37 patients presented with an IFG, 4/37 
patients were admitted with symptoms of hyperglycemia 
(polydipsia, polyuria, fatigue), 1 patient was obese and 
presented with IFG, and 18/37 patients had had monogenic 
DM previously diagnosed in their family. Before the 
confirmation of GCK mutation, 9/37 patients were treated 
as DM1 and in 6/37 cases insulin had been administered.
The mean serum fasting glucose level was 6.67±1.64 
mmol/L and the level ranged between 5.2 and 9.2 mmol/L. 
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According to their blood glucose levels, the patients could 
be divided into three groups: those (4/34 patients) with 
normal values with a glucose level below 5.5 mmol/L (100 
mg/dL), those (10/34 patients) with a glucose level above 
6.9 mmol/L (125 mg/dL) characteristic for DM, and the 
remaining group (20/34) with an IFG 5.5-6.9 mmol/L (100-
125 mg/dL). The profiles for OGTT results were also variable. 
The 120 min glucose level was normal in 8/26 patients and 
lower than 7.8 mmol/L (140 mg/dL). Two of the 26 patients 
had a result characteristic for DM, namely, higher than 11.1 
mmol/L (200 mg/dL), and the remaining patients (16/26) 
had GI with values between 6.9 and 11.1 mmol/L (140-200 
mg/dL). Thus, 12 of the 37 patients (32%) who were CGK-
MODY carriers fulfilled the criteria of DM according to the 
Polish Diabetes Association recommendations (14). This 
figure is equivalent to 12/1043 (1.15%) of all patients with 
DM in our center.
The mean fasting C-peptide level was 2.13±0.65 ng/
mL (normal ranges 0.2-4.2 ng/mL) and in 18/19 cases 
the result was above 0.75 ng/mL. Mean HbA1c level 
at diagnosis was 6.26±0.45 % (44.9 mmol/mol). This 
changed during the diet alone treatment into 6.13±0.39 
% (43.5 mmol/mol) and the difference between the 
results was statistically significant (p<0.013). Six patients 
(6/37) had an elevated LDL cholesterol and five patients 
(5/37) had elevated total cholesterol levels. The mean 
levels of total cholesterol (4.58±1.02  mmol/L), LDL 
cholesterol (2.52±1.02  mmol/L), high-density lipoprotein 
(HDL) cholesterol (1.4±0.23  mmol/L), and triglycerides 
(0.99±0.35 mmol/L) were within normal ranges. 
One patient was obese and one was underweight, the rest 
had BMI results normal for age. Two children (siblings) 
were diagnosed because of short stature and in both cases, 
pathological causes of short stature were excluded. Height 
of the other children were within normal ranges for age and 
compatible with their mid-parental height values. 
Eighteen of the mothers of these children (18/37) had a 
confirmed GCK mutation, usually during family genetic 
tests. Two mothers (2/37) are being treated for DM2. Six 
mothers (6/37) were diagnosed with diabetes during 
pregnancy, found through routine screening, and all of them 
are GCK mutation carriers. In two of their children (2/37), 
birth weights were greater or equal to 4000 g. In both of 
these cases, children had the same GCK mutations as their 
mothers. Three patients (3/37) were small for gestational 
age babies (15). All these patients got their mutations from 
their fathers. Two of them were twins.
The patients presented highly incriminating family histories. 
In the case of 32 patients (32/37) one of the parents (18 
mothers, 12 fathers) was diagnosed with diabetes GCK-
MODY and had the same mutation as her/his child. A clear 
autosomal dominant mode of inheritance was presented. In 
five cases (5/37), the histories are not known. In an interview 
with 21 patients (21/37), diabetes also appears in one of the 
grandparents. The great-grandparents of 4 patients (4/37) 
had a confirmed GCK mutation. 
Autoantibodies typical for DM1 such as islet cell 
autoantibodies (ICA), insulin autoantibodies, glutamic 
acid decarboxylase (GAD) autoantibodies, tyrosine kinase 
autoantibodies, were detected in 2 patients (2/37). One of 
these two patients had all four above-mentioned antibodies 
positive, while only ICA autoantibodies were positive in the 
second patient. Autoimmune diseases were not observed 
in this group of patients. Three patients (3/37) had Gilbert 
disease.
Thirteen mutations of the GCK gene were identified. Eleven 
(11) of these were missense mutations, one nonsense 
mutation, and one deletion (Table 1). The most common 
were p.Gly318Arg (11/36) and p.Val302Leu (8/36). Seven 
subjects with the second mutation (7/8) are members of the 
same family.
The variability of glucose levels was also observed within the 
carriers of the same mutation (p.Gly318Arg, p.Val302Leu).
Regarding the OGTT profile, we observed two different 
patterns in p.Gly318Arg mutation carriers. In 3 of these 11 
patients, the mean increase in plasma glucose level was 5.56 
mmol/L and the 120 min result was typical for DM, whereas 
Table 1. Types of glucokinase mutations in our patients
Type of mutation/Protein effect Number of patients
G>A p.(Gly318Arg) 11
G>C p.(Val302Leu) 8
C>T p.(Ser383Leu) 4
G>A p.(Gly44Asp) 3
delCTT p.(Ser212del) 2
C>A p.(Arg377Gln) 1
A>T p.(Asp198Val) 1
G>A p.(Gly176Arg) 1
G>T p.(Glu157Ter) 1
G>A p.(Val226Met) 1
G>A p.(Glu221Lys) 1
C>A p.(Arg37Gln) 1
T>C p.(Ser212Pro) 1
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in two other subjects (2/11), the mean increase was 1.45 
mmol/L and at 120 min, the glucose level was within the 
normal range. At baseline, the glucose level was increased 
but similar in both groups (5.2-6.7 mmol/L) (Table 2).
A similar situation was observed in the carriers of 
p.Val302Leu mutation. Baseline glucose levels were elevated 
in all patients in this group, ranging from 5.5 mmol/L to 
6.23 mmol/L (Table 3). Three patients (3/8) had a mean 
increase of 0.5 mmol/L in OGTT at 120 min and normal 
glucose levels, while two others (2/8) showed an increase of 
2.95 mmol/L and the glucose levels suggest GI. Presented 
differences had no relationship with the age of the patients.
Discussion
GCK-MODY is mostly described as an asymptomatic 
condition, with mild fasting hyperglycemia (5.5-8 mmol/L), 
minor postprandial glucose extrusion, and a family history 
of diabetes. Usually, only a proper diet is sufficient to 
maintain an appropriate glucose level and prevent diabetic 
complications (1,8,9,10). However, new studies have revealed 
that GCK-MODY patients are not such a homogeneous group 
and that their phenotypes may vary considerably depending 
on the type of mutation (16,17,18). Results of these studies 
indicate that about half of GCK-MODY patients fulfill the 
criteria of DM, while the rest present with IFG or GI (16). 
Missense mutations have variable effects on glucokinase 
activity ranging from a small change in affinity for glucose 
to complete inactivity (19). Analysis of the clinical data of 
our patients led to similar conclusions. The mean features 
of the whole group were similar to those described in the 
literature, although findings pertaining to characteristics 
such as autoantibodies, obesity, fasting glucose levels 
were radically different in some of the patients from those 
characteristics for other types of diabetes. Compared to 
previous reports, we observed a lower percentage (32% vs. 
50%) of GCK-MODY carriers fulfilling the criteria of DM. 
OGTT results of patients with two of the most frequent 
missense mutations (p.Gly318Arg, p.Val302Leu) show that 
their affinity for glucose does not correlate to the type of the 
mutation and even within the same mutation, postprandial 
glucose levels may vary significantly. There is no strong 
correlation between certain types of mutations and plasma 
glucose levels, although the threshold of insulin secretion 
is hypothetically the same. Differences in insulin sensitivity 
(20,21), diet, and physical activity might be probable 
reasons for those findings. Potential roles of other genes 
that modulate GCK function are also possible, considering 
that the GCKR regulatory protein gene has already been 
shown to interact with polymorphisms with GCK in a 
clinically significant way (22,23). GCK mutations affect not 
only the pancreatic function of this enzyme but the liver 
function too, where the decrease in the glycogen synthesis 
and storage, as well as increase in glucogenesis after 
standard meals, is reported. This defect in hepatic glucose 
metabolism contributes to postprandial hyperglycemia of 
GCK-MODY patients (24,25,26).
Our study reports the clinical presentation of 37 patients 
with confirmed GCK-MODY from a single, pediatric centre in 
Central Europe. The analysis of the clinical data includes a 
detailed process of diagnostics and also the assessment of the 
results of GCK-MODY treatment. The diagnosis of GCK-MODY 
was suspected on the basis of atypical signs and symptoms of 
diabetes, or atypical results of treatment, or previous family 
history of GCK-MODY. The limitation of the study is a lack of 
genetic tests in the whole group of 1043 patients with DM 
treated in our department due to financial limitations.
Recent studies report that specific gene mutations can 
present clinically as a neonatal form as well as ‘type 2‐
Table 2. Oral glucose tolerance test profile in p.Gly318Arg 
mutation carriers
Patients with 
p.Gly318Arg 
mutation
Blood 
glucose 
(mmol/L)
0 min
Blood 
glucose 
(mmol/L)
120 min
Increase of 
blood glucose 
in OGTT
(mmol/L)
1 6.7 12.2 5.5
2 5.2 10.9 5.7
3 5.8 11.3 5.5
4 6.4 7.5 1.1
5 6 7.8 1.8
OGTT: oral glucose tolerance test
Table 3. Oral glucose tolerance test profile in 
p.Val302Leu mutation carriers (blood glucose)
Patients with 
p.Val302Leu 
mutation
Blood 
glucose 
(mmol/L)
0 min
Blood 
glucose 
(mmol/L)
120 min
Increase of 
blood glucose 
in OGTT 
(mmol/L)
1 5.5 9.3 3.8
2 6.2 8.3 2.1
3 6.2 6.7 0.5
4 5.6 6.1 0.5
5 6.1 6.6 0.5
OGTT: oral glucose tolerance test
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like’ or ‘type 1‐like’ forms during adulthood (27) which 
makes diagnosis very difficult especially when symptoms, 
laboratory tests, and phenotype correspond to ‘double’ 
diabetes or even ‘triple’ diabetes with features of DM1, 
DM2, and presence of monogenic mutation. It is not an 
exception that patients with GCK-MODY are diagnosed as 
DM1 and treated with insulin. According to the literature, 
those subjects require higher than replacement doses to 
improve metabolic control of DM (28) and it may be a reason 
for their physicians to extend their diagnosis. In our group 
of patients, two boys presented with such inexplicably high 
requirement for insulin, whereas in another four children, 
the requirement for insulin was lower than that of other 
patients with DM1. These facts together with a strong 
positive family history of DM should also lead to a suspicion 
of monogenic diabetes.
Despite wide ranging glucose levels, HbA1c values were 
similar in all patients and mean levels were below the 
10th percentile for diabetic children (22). Furthermore, 
we observed a significant reduction of HbA1c levels after 
treatment with diet alone. Reported fasting C-peptide levels 
above 0.75, persisting for 3-5 years from diagnosis, are 
suggestive of DM2 or monogenic diabetes. Similar values 
are consistent with short-term insulin independence in 
an individual who has not previously ‘failed’ non-insulin 
therapy but may occur in the DM1 diabetes honeymoon 
period (29).
The prevalence of dyslipidemia encountered in some 
patients may occur in GCK-MODY but is characteristic rather 
for DM2 (19,30). The carriers of GCK mutations usually show 
lower levels of fatty acids and triglycerides in circulation than 
the healthy population (31). Reduced GCK activity is likely 
to reduce glycolytic flux and production of both glycogen 
and malonyl-CoA. The latter is an important regulator of 
lipid metabolism; reduced levels alleviate inhibition of 
carnitine palmityl transferase 1, thereby increasing fatty 
acid oxidation. In addition, malonyl-CoA is the precursor 
of fatty acid synthesis; this will potentially also be reduced 
when GCK activity drops. Moreover, esterification of fatty 
acids into TAGs would be insufficient owing to reduced 
production of glycerol-3-phosphate via glycolysis. Thus, 
overall, hepatic fatty acid and TAG production and glucose 
metabolism would be decreased in the face of reduced GCK 
activity (31). Moreover, HDL cholesterol values measured in 
individuals with likely monogenic diabetes may be useful in 
screening for GCK-MODY and its differentiation from DM1 
and HNF1A-MODY, regardless of treatment or metabolic 
control (12). The studies performed by Fendler et al (32) 
showed that individuals with GCK-MODY exhibit a strongly 
protective profile HDL cholesterol (high concentration of 
large HDL and low levels of intermediate and small HDL 
subpopulation). Next to constitutively moderately elevated 
glycemia observed in these patients, this lipid profile 
may be also a factor contributing to the low frequency of 
cardiovascular complications (32).
A twofold increase in incidence of Gilbert disease in our 
patients compared to the general population appears to be 
due to inter-family relationships in some of these individuals.
The positive GAD antibodies observed in two patients are 
not characteristic for GCK-MODY. The prevalence of GAD 
antibodies and a confirmed genetic diagnosis of MODY 
may represent the 1-2% of the population with detectable 
islet antibodies with no associated pathogenesis. In general, 
the finding of islet autoantibodies makes the diagnosis of 
MODY very unlikely, and genetic testing should only be 
performed if other clinical characteristics strongly suggest 
this form of diabetes rather than DM1 (33). Furthermore, 
positive diabetes autoantibodies can be transient in GCK-
MODY patients and are not markers of prediabetes. It is 
possible that autoantibody titers are aggravated by obesity 
or by other factors, such as drugs (34).
Individuals with GCK-MODY are usually not obese and achieve 
normal growth. The imposition of obesity cannot be excluded, 
in view of the overall increase in obesity in all populations.
Large population cohort studies of pregnant women estimate 
the population prevalence of GCK-MODY as 1.1 in 1000 
(35,36). The percentage of mutations in females diagnosed 
with diabetes in pregnancy could be significantly greater. 
Most importantly, maternal hyperglycemia in pregnancy 
is the primary risk factor for newborn macrosomia caused 
by fetal hiperinsulinism. GCK-MODY patients present with 
good, sometimes even high, insulin production and function 
but have increased set point stimulated insulin secretion. 
Usually babies with maternally inherited GCK-MODY 
and which have an increased set point stimulated insulin 
secretion, secrete a normal amount of insulin with maternal 
hyperglycemia, and have normal birth weights. Very 
high maternal hyperglycemia could result in fetal insulin 
hypersecretion, and ultimately, an overweight newborn, as 
was the case in two of our patients. The low birth weight 
observed in our three patients with paternally inherited 
GCK-MODY and non-diabetic mothers may be an effect of 
fetal hyperglycemia due to GCK mutation. Hyperglycemia in 
these cases is a result of low insulin secretion in the milieu 
of maternal normoglycemia due to increased set point 
stimulated insulin secretion.
According to the guidelines for GCK-MODY diagnosis, mild 
fasting hyperglycemia (5.5-8.0 mmol/L), small increase in 
OGTT (<4.6 mmol/L) at 120 min, negative autoantibodies, 
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and MODY diagnosed in one of the parents are key 
indications for the genetic screening for GCK mutations. 
Our study shows that the diagnosis of this type of diabetes 
is more challenging in some cases. The phenotype of GCK-
MODY patients may vary from one that is characteristic of 
other types of diabetes to an asymptomatic state with normal 
fasting glucose levels. Differences in insulin sensitivity, diet, 
and physical activity may be the probable causes of these 
findings. Potential roles of other genes modulating GCK 
function are also possible. The most important observation 
is that the proper diagnosis of GCK-MODY could lead to 
cessation of insulin treatment with improvement in the 
patients’ quality of life.
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